Morquio A syndrome may be seen in adults, but FDA classified it as a rare pediatric disease because it begins in childhood and many patients with a severe form of the syndrome do not survive to adulthood.
The decision meant that BioMarin Pharmaceutical Inc. was eligible for (and ultimately received) the first rare pediatric disease priority...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?